Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.54 |
| ▸ | TNF | P01375 | 4/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.54 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.54 |
| ▸ | AXL | P30530 | 5/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | GPX4 | P36969 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24830078 | 0.91 | TNF (0.56) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL26840009 | 0.91 | MAP1LC3B (0.62) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL30042173 | 0.90 | MAP1LC3B (0.56) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL25238550 | 0.90 | MAP1LC3B (0.56) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL26814240 | 0.90 | MAP1LC3B (0.63) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL26814272 | 0.90 | MAP1LC3B (0.63) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL29260092 | 0.87 | MAP1LC3B (0.52) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL24142000 | 0.86 | CRBN (0.61) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL21814682 | 0.86 | CRBN (0.61) | CRBNTNFIKZF3DDB1BRD4 | |
| SCHEMBL22636509 | 0.86 | CRBN (0.61) | CRBNTNFIKZF3DDB1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 1386/4885TNF 2783/4885IKZF3 1006/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | CRBN 1386/4885TNF 2783/4885IKZF3 1006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.